Will Cabazitaxel Success Derail Other Prostate Cancer Trials?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The release of positive Phase III results for Sanofi-Aventis' next-generation chemotherapy agent cabazitaxel in hormone-resistant prostate cancer could put a damper on recruitment for clinical trials of other late-stage drug trials in the same indication
You may also be interested in...
Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop
The Phase III failure of the high-profile Alzheimer's disease drug dimebon is a setback not only for Alzheimer's drug development, but also for Pfizer, which very much needs pipeline successes to offset upcoming patent losses, and for Medivation, whose near-term future hinges on the drug
Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop
The Phase III failure of the high-profile Alzheimer's disease drug dimebon is a setback not only for Alzheimer's drug development, but also for Pfizer, which very much needs pipeline successes to offset upcoming patent losses, and for Medivation, whose near-term future hinges on the drug
Unknown Timing of Lovenox Generics Complicates Sanofi-Aventis' Outlook
LONDON - Sanofi-Aventis CEO Chris Viehbacher appeared uncomfortable discussing the expected timing of generic competition to Lovenox (enoxaparin) during a Feb. 10 earnings call